Qhslab, INC 8-K filings

QHSLab, Inc. announced robust second quarter and first half 2026 financial results, highlighted by an over 86% increase in Integrated Service Program (ISP) revenue and expanding gross margins.

QHSLab, Inc. announced its participation in the Planet MicroCap Las Vegas 2026 conference, with plans to present its business overview and strategy to investors.

QHSLab, Inc. announced unaudited April 2026 revenue of $325,889, a 57% increase year-over-year, and introduced a new independent representative program called QHS Practice Access Network (PAN).

QHSLab, Inc. announced a 127% year-over-year increase in its Integrated Service Program (ISP) revenue for Q1 2026, reaching $370,000, and launched a new Q-Connect GLP-1 Support Assessment.

QHSLab, Inc. announced robust fiscal year 2025 financial results, showcasing significant revenue growth, expanding margins, and substantial balance sheet improvements driven by its Integrated Service Program.

QHSLab Inc. announced preliminary unaudited 2025 financial results, showcasing over 25% revenue growth, expanded gross margins, and significant convertible debt reduction.

QHSLab, Inc. has repurchased and cancelled a $470,529 promissory note held by MedScience Research Group, Inc. by issuing 1,568,432 shares of common stock.

QHSLab Inc. initiates a formal process to expand its board of directors with independent members to strengthen governance and support future growth.

QHSLab Inc. announced unaudited financial and operational updates, highlighting 32% revenue growth, positive operating income, and significant convertible debt reduction ahead of its January 2026 investor session.

QHSLab, Inc. converted a significant portion of a convertible promissory note into common stock and extended the maturity date for the remaining balance.

QHSLab, Inc. announced the completion of a $500,000 private placement and the retirement of over $1.4 million in legacy convertible debt, positioning the company for focused growth in 2026.

QHSLab Inc. announced the launch of Q-Cog, a cloud-based cognitive assessment tool designed to aid primary care providers in the early detection of Mild Cognitive Impairment and dementia.

QHSLab, Inc. announced the furnishing of its December 2025 Corporate Presentation, detailing its business and operations.

QHSLab, Inc. announced accelerating revenue growth, expanding gross margins, and the full retirement of convertible notes, significantly strengthening its balance sheet and removing dilution risk.

QHSLab, Inc. announced the repurchase and retirement of over $1.4 million in legacy convertible debt for $300,000, significantly strengthening its balance sheet and reducing future dilution.

QHSLab Inc. announced the launch of its new Pediatric Health Assessment, a digital screening tool linking allergies and mental health, now live with a multi-location pediatric group in Texas.

QHSLab, Inc. announced the opening of its first co-branded QHS Behavioral Healthcare Center in Miami, integrating digital health tools with in-person mental health services to create new revenue streams and address the nationwide mental health crisis.

QHSLab, Inc. announced the publication of two peer-reviewed studies validating its digital assessment tools for enhancing patient outcomes and healthcare efficiency, supporting future revenue growth and provider adoption.

QHSLab, Inc. released its May 2025 corporate presentation detailing the company's business and operations.

QHSLab Inc. is in advanced talks with Catheter Precision, Inc. to restructure its debt, aiming to improve financial flexibility and reduce dilution risk.

QHSLab, Inc. announces a 32% year-over-year increase in revenue and expanded gross margins for the quarter ended March 31, 2025.

QHSLab Inc. has engaged Hayden IR to enhance its investor relations program and broaden its reach within the investment community.

QHSLab, Inc. received a default notice from Mercer Street Global Opportunity Fund, LLC regarding outstanding convertible promissory notes totaling approximately $1.4 million in principal and interest.

QHSLab, Inc. announces record revenue growth and its first profitable year in 2024, driven by a 98% revenue surge in Q4 compared to the previous year.

QHSLab and Town Total Compounding are partnering to expand market reach and enhance patient care through integrated digital health and customized pharmacy solutions.

QHSLab, Inc. released its January 2025 corporate presentation detailing the company's business and operations.

QHSLab, Inc. will be exhibiting at the Pri-Med South conference in Fort Lauderdale, Florida, from February 6-8, 2025, targeting primary care professionals.

QHSLab details its business model, revenue streams, and growth plans, targeting $10 million in annual revenue by scaling its physician network.

QHSLab and South Dakota State University have received an invitation from the National Science Foundation to submit a full application for their AIR-GUIDDE technology, a platform designed to improve drug delivery.

QHSLab Inc. reports significant progress in digital health innovation, research recognition, and revenue growth for 2024, including a 110% sales increase in October.